# uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

> **NCT05874921** · — · RECRUITING · sponsor: **UroGen Pharma Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Urothelial Carcinoma
- Urothelial Carcinoma Recurrent
- Urothelial Carcinoma Ureter
- Urothelial Carcinoma Ureter Recurrent
- Urothelial Cancer of Renal Pelvis
- Urothelial Carcinoma of the Renal Pelvis and Ureter
- Carcinoma, Transitional Cell
- Transitional Cell Carcinoma of Renal Pelvis

## Interventions

- **DRUG:** Jelmyto (mitomycin) for pyelocalyceal solution

## Key facts

- **NCT ID:** NCT05874921
- **Lead sponsor:** UroGen Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-17
- **Primary completion:** 2026-04
- **Final completion:** 2028-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874921, "uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05874921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*